自拟降脂散治疗高脂血症的临床研究
|
摘要
高脂血症是指由于脂肪代谢或转运异常使血浆中一种或几种脂质高于正常,可表现为高胆固醇血症,高甘油三酯血症,或两者兼有(混合型高脂血症)。近年来,随着人们生活水平的提高,社会老龄化程度的加重,疾病模式也发生了改变,传染病逐渐减少而心脑血管疾病逐年增加,成为当前影响人类健康,危害人类生命最重,发病率最高,死亡率和致残率最高的三大疾病之一。大量研究资料表明,高脂血症是脑卒中、心脏猝死、心肌梗死、冠心病等重要而独立的危险因素,而使用调脂药物纠正血脂异常,已被证实可以改善内皮功能障碍、减慢粥样硬化斑块的进展、降低心肌缺血和急性冠状动脉综合征的发病率及致死率,是心脑血管疾病一级预防和二级预防的有力措施。所以医学界非常重视对高血脂的研究,如何有效的调节血脂水平,对于防治心脑血管疾病有重要的意义。肝脏是血脂代谢的重要场所,调脂药物也主要在肝脏作用,调脂药物的肝脏毒性是妨碍其临床应用的原因之一。中医药对高脂血症的认识有其独特的理论,大量小样本临床研究证实具有较好的疗效。自拟降脂散为纯中药制剂,本研究应用此药物观察其对于血脂异常的作用,希望为临床医生提供一种安全有效的调脂药物。
目的
观察自拟降脂散治疗高脂血症的临床疗效和安全性,以期为临床应用提供安全性和药效学依据。
方法
1.病例纳入标准(同时符合以下四条,方可纳入观察病例)
(1)符合中医辨证及西医诊断标准。符合上述高脂血症诊断的高脂血症病人。
(2)年龄在18-70岁之间。
(3)虽服用调脂药物,但已停药两周以上,血脂水平仍符合诊断标准。
(4)患者志愿受试并签署知情同意书。
2.病例排除标准(符合以下任何1条,不得纳入观察病例)
(1)不符合中医辨证及西医诊断标准。不符合上述诊断标准和纳入标准者。
(2)半年内患有心肌梗塞、脑血管意外、严重创伤或做过重大手术者。
(3)肾病综合症、甲状腺功能减退、急性和慢性肝胆疾病、糖尿病及痛风病人。
(4)由药物引起的高脂血症。
(5)正在使用肝素、甲状腺治疗药和其他影响血脂代谢药的病人以及近4周内
(6)采用其他降血脂措施的病人。
(7)孕妇及哺乳期妇女。
(8)合并有其他严重器质性病变,医生认为不适合者。
(9)过敏体质及精神病病人。
3.病例分组
全部病例均来源于台湾东肠中医诊所就诊病人60例。西医诊断为高脂血症,中医分型为痰浊阻遏证、脾肾阳虚证、肝肾阴虚证、气滞血瘀证、阴虚阳亢证。采用随机对照试验方法,将合格受试者以1：1的比例分配至治疗组和对照组,每组30例,整个实验过程中无病例脱落。两组病例在人口学资料、一般生命体征、病情资料等方面比较,经统计学分析处理无显著性差异,P>0.05,具有可比性。
4.治疗方法
(1)治疗组：自拟降脂散,研末装胶囊口服,每次9g,每日3次,疗程60天。
(2)对照组：胆固醇清片(制造商：加拿大Omega Inc,规格：240粒／瓶,450mg／粒,准字号：300091)
5.观察指标
(1)安全性观测
①一般体格检查项目(含体重、血压、心率)。
②血、尿、粪常规化验。
③心电图检查,肝、肾功能检查。
以上项目治疗前3天内,疗程结束±3天内各检测1次,共两次。
(2)疗效性观测(对观察做相关统计学分析处理)
①相关症状与体征：治疗前3天内观察记录1次,治疗过程中每两周察记录1次,直至治疗结束。
②体重：治疗前3天内观察记录1次,治疗过程中每周观察记录1次,直至治疗结束。
③血脂检测：检测(计算)TC、TG、HDL-c、LDL-c等,治疗前、后3天内各一次。
④载脂蛋白apoAI、apoB100测定,治疗前、治疗后3天内各一次。
⑤血液流变学测定：检测全血比粘度(高切、低切)、血浆比粘度、血沉、红细胞压积,治疗前、治疗后3天内各一次。
结果
1.对两组治疗前后临床综合症状总疗效比较,差异有统计学意义(秩和检验,P<0.01),其中两组总有效率的比较经卡方检验差异亦有统计学意义,可认为治疗组疗效高于对照组。
2.对两组中医单项症状疗效比较,头晕症状、腹胀纳呆症状、头痛症状、肢麻沉重症状、心悸症状、失眠症状、胸闷痛症状、二便异常症状两组改善程度,差异有统计学意义(秩和检验,P<0.05),可认为治疗组中医单项症状的改善优于对照组。
3.对两组治疗后中医单项症状消失率比较,在头晕、头痛、肢麻沉重、失眠、胸闷痛、二便异常症状消失率比较上,差异有统计学意义(卡方检验,P<0.05),可认为治疗组单项症状的消失率高于对照组。
4.对两组治疗前后舌象、脉象变化比较,舌淡胖、苔滑腻、脉弦滑消失率比较,差异有统计学意义(卡方检验,P<0.05),可认为治疗组消失率高于对照组。
5.对治疗前后血脂指标(TC、TG、HDL-C、LDL-C、Lp(a))变化,两组组内比较,差异有统计学意义(配对t检验,P<0.05),提示经治疗后两组病例的高血脂状态得到明显改善；两组组间比较,两组治疗后TC、HDL-C的比较,差异有统计学意义(成组t检验,P<0.05)。
6.对治疗前后载脂蛋白(apoAI、apoB100)变化,两组组内比较,差异有统计学意义(配对t检验,P<0.05),提示经治疗后两组病例的该类指标改善明显；两组治疗后组间比较,提示组间比较差异无统计学意义(成组t检验,P>0.05)。
7.对治疗前后血流变指标(全血粘度高切、全血粘度低切、血浆比粘度、)变化,两组组内比较,差异有统计学意义(配对t检验,P<0.05),提示经治疗后两组病例的该类指标均改善明显；两组治疗后组间比较,两组治疗后全血粘度低切、血浆比粘度、血沉、红细胞压积、纤维蛋白原比较,差异有统计学意义(成组t检验,P<0.05)。
结论
本次临床研究表明,自拟降脂散能有效地降低各项相关实验室指,改善证候症状,治疗高脂血症。在服药过程当中,对肝、肾功能、血常规关安全性指标没有明显影响,是一种安全有效的用药途径,发挥了中医药势,为临床的推广使用提供了有利的理论依据。
Objective
Hyperlipidemia is due to abnormal fat metabolism or abnormal transport which causing one or more kind of lipid in plasma became higher than normal, can be reflected as hypercholesterolemia、hypertriglyceridemia, or both (mixed high lipemia). In recent years, with the development of people's living standards、the aging of societ have became worse and worse and the changed mode of the disease, contagious disease has tapered while cerebrovascular diseases has increased year by year, which become one of the three diseases of hightest effection on affecting human health, harming to human life, attacking rate, death rate and mutilation rate. A lot of research data was showed that hyperlipidemia was one of the independent risk factor of sudden cardiac death, myocardial infarction, coronary heart disease and so on, using lipid lowering drugs to correct dyslipidemia was a good powerful measure to the first-level prevention and the second-level prevention of cerebrovascular diseases by improving endothelial dysfunction, slowing porridge the progress of atherosclerotic plaque and reducing myocardial ischemia and acute coronary syndrome and mortality rates. Medical science community paid more attention on the research of the hyperlipemia which has important significance of preventing cardiovascular disease. The liver is an important site for blood-fat metabolism and adjusting cholesterol. The hepatotoxicity was a main reason for obstruct its clinical application. Traditional Chinese Medicine has its unique understanding on hyperlipoidemia which has been confirmed has the better curative effect on a large number of small sample size clinical research. The study that used Ziningjiangzhi powder (ZNP) was to observe the abnormal effect of blood-fat hoping to provide a safe and effective lipid lowering drugs for clinic.
Literature review:Studied the Chinese medicine on the pathogenesis of hyperlipidemia and the information of determination of treatment based in pathogenesis obtained through differentiation of symptom and sign, we had a more comprehensive understanding of high blood lipids and overview of the development of recent drug using in disease, and summed up summary and statement. From the western medicine, provided comprehensive overview on the concept of hyperlipidemia、classification and diagnosis, also summed up the progress of drug therapy of lowering fat and got the review evaluation from clinical trials in recent years.
Methods
To observe the efficacy and safety of Ziningjiangzhi powder for treated Hyperlipidemia in order to provide the pharmacodynamic and safety basis for clinical application. Methods
1. Cases internalized criteria (also subject to the following four titles)
(1) Meeting the diagnostic criteria of TCM and western medicine and consisting with the diagnosis of hyperlipidemia hyperlipidemia.
(2) During 18 to70 years old.
(3) Although taken lipid lowering drugs, stopped using more than two weeks, the level of blood fat still met the diagnostic criteria.
(4) Subjects were volunteers and signed informed consent.
2. Cases exclusion criteria (in accordance with any of the following one)
(1) Not meet the diagnostic criteria of TCM and western medicine, and do not meet these diagnostic criteria and inclusion standards.
(2)Suffered from myocardial infarction、cerebrovascular accidents、major trauma or major surgery during six months.
(3) Nephrotic syndrome, thyroid dysfunction, acute and chronic liver and gallbladder disease, diabetes and gout patients.
(4)Hyperlipemia induced by drugs.
(5)Patients were used heparin and other drug that treating thyroid or effecting blood-fat metabolism for nearly 4 weeks
(6) Patients were used other lipid-lowering measures.
(7) Pregnant and lactating women.
(8)The people that were associated with other serious organic disease and doctors diagnosed as incompetence
(9) Patients who had allergies and mental disease.
3. Case divided
60 patients were all collected in Taiwan Dongyang clinic in TCM and diagnosed as hyperlipidemia in western medicine with typed of repression for the sputum、asdthenic splenonephro-yang、hepatic and renal yin deficiency、qi-stagnancy and blood stasis、asthenic yin causing predominant yang in TCM. The qualified patients were randomly divided at 1:1 ratio into 2 groups:the treatment group and the control group, each group was 30 cases and no cases of absence. Two groups of patients in demographics、general life signs、the condition data and so on have no significant difference(P> 0.05).
4. Treatment methods:
(1) The treatment group:given ZNP in caps orally,9g for each time,3 times a day,60days as a course of treatment.
(2) The control group:given cholesterol clearing pellet (Manufacturer:Canada Omega Inc, Specification:240/bottle,450mg/tablets, quasi-number:300091)
5. Observation of index
1. Safety tested:
(1) General physical examination items (including weight, blood pressure, heart rate).
(2) Blood, urine, stool routine tests.
(3) Electrocardiogram test, liver and kidney function tests. Before treatment, above 3 days, at the end of treatment±3 days, once at each test, two times in total.
2. Observation of effect (do statistical analysis related observation)
(1) Symptoms and signs:to observe and record one time in 3 days before treatment, and record symptoms and signs one time in every two weeks during the treatment, till the end.
(2) Weight:to observe and record one time in 3 days before treatment, and record one time in every two weeks during the treatment, till the end.
(3) Blood-fat test:detection (calculated) TC, TG, HDL-c, LDL-c, etc., one time respectively in before and end of 3 days of the treatment time.
(4) To measure the apolipoprotein apoAI, apoB100 one time in before and end of 3 days of the treatment time respectively.
(5) Hemorrheology:detection of whole blood viscosity (high shear, low shear), plasma viscosity, erythrocyte sedimentation rate and hematocrit one time respectively in before and end of 3 days of the treatment time.
Results
1. There was significant differences between two groups of before and after treatment by the using rank sum test (P<0.01), and the total curative effect effective comparison of two groups by chi-square test was statistically significant. It was considered that the curative effect in the treatment group was higher than that of in the control group.
2. Using rank sum test to compare the treatment group with the control group in efficacy of individual symptoms of Traditional Chinese Medicine, there was statistically significance between than two groups in dizziness, abdominal distension and anorexia symptoms, headache, heavy limbs numbness symptoms, palpitation, insomnia, chest pain symptoms, urine and stool abnormal symptoms (P<0.05). It was considered the treatment group of efficacy of individual symptoms of Traditional Chinese Medicine improved individual symptoms better than that of the control group.
3. Using chi square test to compare one group with the other group in the disappearance rate of efficacy of individual symptoms of Traditional Chinese Medicine after treatment, shows that in dizziness, headache, heavy limbs numbness, insomnia, chest pain, abnormal symptoms in the urine and stool, we compare the rate of%, the difference was statistically significance (P<0.05), can be considered individual symptoms in the treatment group rate was higher.
4. There was statistical significance compared before treatment with after treatment in tongue demonstration and pulse tracings,in which tongue pale, creamy fur, slippery pulse rate% loss of comparison by using chi square test to two group(P<0.05). It was considered the disappearance rate of the treatment group was higher.
5. There was statistical significance compared with the lipid parameters (TC, TG, HDL-C, LDL-C, Lp (a)) changes before and after treatment in both group by using paired t-test(P<0.05). It was showed that two cases of high blood lipid status had significantly improved. There was statistical significance between the two groups by t-test on the difference of TC> HDL-C. (P<0.05)
6. There was statistical significance between two groups using paired t test on the change of apolipoprotein (apoAI, apoB100) before and after treatment (P<0.05). It was showed that the two groups were remarkable improvements after treatment. The difference between groups had not statistical significance compared with two groups after treatment by using group t-test. (P>0.05).
7. There was significant difference between two groups of changes before and after treatment on the Hemorheological indexes (whole blood viscosity, high shear, low shear whole blood viscosity, plasma viscosity) by using paired t-test (P<0.05). It was showed that the two groups of such case indicators were improving significantly after treatment. The difference of plasma viscosity, erythrocyte sedimentation rate, hematocrit product, fibrinogen had statistical significance compared within groups after treatment by using paired t-test. (P<0.05)
Conclusion
The clinical study had shown that Jiang ZNP could effectively reduce the bulk lipid of the relevant laboratory index and could improve the syndrome symptoms and treatment of hyperlipidemia. In the process of taken medication, there was not significantly difference on the liver-kidney function, blood routine test, It was a safe and effective treatment medicine promoting the advantage of TCM and provided the theoretical basis for the further clinical application.
目的
观察自拟降脂散治疗高脂血症的临床疗效和安全性,以期为临床应用提供安全性和药效学依据。
方法
1.病例纳入标准(同时符合以下四条,方可纳入观察病例)
(1)符合中医辨证及西医诊断标准。符合上述高脂血症诊断的高脂血症病人。
(2)年龄在18-70岁之间。
(3)虽服用调脂药物,但已停药两周以上,血脂水平仍符合诊断标准。
(4)患者志愿受试并签署知情同意书。
2.病例排除标准(符合以下任何1条,不得纳入观察病例)
(1)不符合中医辨证及西医诊断标准。不符合上述诊断标准和纳入标准者。
(2)半年内患有心肌梗塞、脑血管意外、严重创伤或做过重大手术者。
(3)肾病综合症、甲状腺功能减退、急性和慢性肝胆疾病、糖尿病及痛风病人。
(4)由药物引起的高脂血症。
(5)正在使用肝素、甲状腺治疗药和其他影响血脂代谢药的病人以及近4周内
(6)采用其他降血脂措施的病人。
(7)孕妇及哺乳期妇女。
(8)合并有其他严重器质性病变,医生认为不适合者。
(9)过敏体质及精神病病人。
3.病例分组
全部病例均来源于台湾东肠中医诊所就诊病人60例。西医诊断为高脂血症,中医分型为痰浊阻遏证、脾肾阳虚证、肝肾阴虚证、气滞血瘀证、阴虚阳亢证。采用随机对照试验方法,将合格受试者以1：1的比例分配至治疗组和对照组,每组30例,整个实验过程中无病例脱落。两组病例在人口学资料、一般生命体征、病情资料等方面比较,经统计学分析处理无显著性差异,P>0.05,具有可比性。
4.治疗方法
(1)治疗组：自拟降脂散,研末装胶囊口服,每次9g,每日3次,疗程60天。
(2)对照组：胆固醇清片(制造商：加拿大Omega Inc,规格：240粒／瓶,450mg／粒,准字号：300091)
5.观察指标
(1)安全性观测
①一般体格检查项目(含体重、血压、心率)。
②血、尿、粪常规化验。
③心电图检查,肝、肾功能检查。
以上项目治疗前3天内,疗程结束±3天内各检测1次,共两次。
(2)疗效性观测(对观察做相关统计学分析处理)
①相关症状与体征：治疗前3天内观察记录1次,治疗过程中每两周察记录1次,直至治疗结束。
②体重：治疗前3天内观察记录1次,治疗过程中每周观察记录1次,直至治疗结束。
③血脂检测：检测(计算)TC、TG、HDL-c、LDL-c等,治疗前、后3天内各一次。
④载脂蛋白apoAI、apoB100测定,治疗前、治疗后3天内各一次。
⑤血液流变学测定：检测全血比粘度(高切、低切)、血浆比粘度、血沉、红细胞压积,治疗前、治疗后3天内各一次。
结果
1.对两组治疗前后临床综合症状总疗效比较,差异有统计学意义(秩和检验,P<0.01),其中两组总有效率的比较经卡方检验差异亦有统计学意义,可认为治疗组疗效高于对照组。
2.对两组中医单项症状疗效比较,头晕症状、腹胀纳呆症状、头痛症状、肢麻沉重症状、心悸症状、失眠症状、胸闷痛症状、二便异常症状两组改善程度,差异有统计学意义(秩和检验,P<0.05),可认为治疗组中医单项症状的改善优于对照组。
3.对两组治疗后中医单项症状消失率比较,在头晕、头痛、肢麻沉重、失眠、胸闷痛、二便异常症状消失率比较上,差异有统计学意义(卡方检验,P<0.05),可认为治疗组单项症状的消失率高于对照组。
4.对两组治疗前后舌象、脉象变化比较,舌淡胖、苔滑腻、脉弦滑消失率比较,差异有统计学意义(卡方检验,P<0.05),可认为治疗组消失率高于对照组。
5.对治疗前后血脂指标(TC、TG、HDL-C、LDL-C、Lp(a))变化,两组组内比较,差异有统计学意义(配对t检验,P<0.05),提示经治疗后两组病例的高血脂状态得到明显改善；两组组间比较,两组治疗后TC、HDL-C的比较,差异有统计学意义(成组t检验,P<0.05)。
6.对治疗前后载脂蛋白(apoAI、apoB100)变化,两组组内比较,差异有统计学意义(配对t检验,P<0.05),提示经治疗后两组病例的该类指标改善明显；两组治疗后组间比较,提示组间比较差异无统计学意义(成组t检验,P>0.05)。
7.对治疗前后血流变指标(全血粘度高切、全血粘度低切、血浆比粘度、)变化,两组组内比较,差异有统计学意义(配对t检验,P<0.05),提示经治疗后两组病例的该类指标均改善明显；两组治疗后组间比较,两组治疗后全血粘度低切、血浆比粘度、血沉、红细胞压积、纤维蛋白原比较,差异有统计学意义(成组t检验,P<0.05)。
结论
本次临床研究表明,自拟降脂散能有效地降低各项相关实验室指,改善证候症状,治疗高脂血症。在服药过程当中,对肝、肾功能、血常规关安全性指标没有明显影响,是一种安全有效的用药途径,发挥了中医药势,为临床的推广使用提供了有利的理论依据。
Objective
Hyperlipidemia is due to abnormal fat metabolism or abnormal transport which causing one or more kind of lipid in plasma became higher than normal, can be reflected as hypercholesterolemia、hypertriglyceridemia, or both (mixed high lipemia). In recent years, with the development of people's living standards、the aging of societ have became worse and worse and the changed mode of the disease, contagious disease has tapered while cerebrovascular diseases has increased year by year, which become one of the three diseases of hightest effection on affecting human health, harming to human life, attacking rate, death rate and mutilation rate. A lot of research data was showed that hyperlipidemia was one of the independent risk factor of sudden cardiac death, myocardial infarction, coronary heart disease and so on, using lipid lowering drugs to correct dyslipidemia was a good powerful measure to the first-level prevention and the second-level prevention of cerebrovascular diseases by improving endothelial dysfunction, slowing porridge the progress of atherosclerotic plaque and reducing myocardial ischemia and acute coronary syndrome and mortality rates. Medical science community paid more attention on the research of the hyperlipemia which has important significance of preventing cardiovascular disease. The liver is an important site for blood-fat metabolism and adjusting cholesterol. The hepatotoxicity was a main reason for obstruct its clinical application. Traditional Chinese Medicine has its unique understanding on hyperlipoidemia which has been confirmed has the better curative effect on a large number of small sample size clinical research. The study that used Ziningjiangzhi powder (ZNP) was to observe the abnormal effect of blood-fat hoping to provide a safe and effective lipid lowering drugs for clinic.
Literature review:Studied the Chinese medicine on the pathogenesis of hyperlipidemia and the information of determination of treatment based in pathogenesis obtained through differentiation of symptom and sign, we had a more comprehensive understanding of high blood lipids and overview of the development of recent drug using in disease, and summed up summary and statement. From the western medicine, provided comprehensive overview on the concept of hyperlipidemia、classification and diagnosis, also summed up the progress of drug therapy of lowering fat and got the review evaluation from clinical trials in recent years.
Methods
To observe the efficacy and safety of Ziningjiangzhi powder for treated Hyperlipidemia in order to provide the pharmacodynamic and safety basis for clinical application. Methods
1. Cases internalized criteria (also subject to the following four titles)
(1) Meeting the diagnostic criteria of TCM and western medicine and consisting with the diagnosis of hyperlipidemia hyperlipidemia.
(2) During 18 to70 years old.
(3) Although taken lipid lowering drugs, stopped using more than two weeks, the level of blood fat still met the diagnostic criteria.
(4) Subjects were volunteers and signed informed consent.
2. Cases exclusion criteria (in accordance with any of the following one)
(1) Not meet the diagnostic criteria of TCM and western medicine, and do not meet these diagnostic criteria and inclusion standards.
(2)Suffered from myocardial infarction、cerebrovascular accidents、major trauma or major surgery during six months.
(3) Nephrotic syndrome, thyroid dysfunction, acute and chronic liver and gallbladder disease, diabetes and gout patients.
(4)Hyperlipemia induced by drugs.
(5)Patients were used heparin and other drug that treating thyroid or effecting blood-fat metabolism for nearly 4 weeks
(6) Patients were used other lipid-lowering measures.
(7) Pregnant and lactating women.
(8)The people that were associated with other serious organic disease and doctors diagnosed as incompetence
(9) Patients who had allergies and mental disease.
3. Case divided
60 patients were all collected in Taiwan Dongyang clinic in TCM and diagnosed as hyperlipidemia in western medicine with typed of repression for the sputum、asdthenic splenonephro-yang、hepatic and renal yin deficiency、qi-stagnancy and blood stasis、asthenic yin causing predominant yang in TCM. The qualified patients were randomly divided at 1:1 ratio into 2 groups:the treatment group and the control group, each group was 30 cases and no cases of absence. Two groups of patients in demographics、general life signs、the condition data and so on have no significant difference(P> 0.05).
4. Treatment methods:
(1) The treatment group:given ZNP in caps orally,9g for each time,3 times a day,60days as a course of treatment.
(2) The control group:given cholesterol clearing pellet (Manufacturer:Canada Omega Inc, Specification:240/bottle,450mg/tablets, quasi-number:300091)
5. Observation of index
1. Safety tested:
(1) General physical examination items (including weight, blood pressure, heart rate).
(2) Blood, urine, stool routine tests.
(3) Electrocardiogram test, liver and kidney function tests. Before treatment, above 3 days, at the end of treatment±3 days, once at each test, two times in total.
2. Observation of effect (do statistical analysis related observation)
(1) Symptoms and signs:to observe and record one time in 3 days before treatment, and record symptoms and signs one time in every two weeks during the treatment, till the end.
(2) Weight:to observe and record one time in 3 days before treatment, and record one time in every two weeks during the treatment, till the end.
(3) Blood-fat test:detection (calculated) TC, TG, HDL-c, LDL-c, etc., one time respectively in before and end of 3 days of the treatment time.
(4) To measure the apolipoprotein apoAI, apoB100 one time in before and end of 3 days of the treatment time respectively.
(5) Hemorrheology:detection of whole blood viscosity (high shear, low shear), plasma viscosity, erythrocyte sedimentation rate and hematocrit one time respectively in before and end of 3 days of the treatment time.
Results
1. There was significant differences between two groups of before and after treatment by the using rank sum test (P<0.01), and the total curative effect effective comparison of two groups by chi-square test was statistically significant. It was considered that the curative effect in the treatment group was higher than that of in the control group.
2. Using rank sum test to compare the treatment group with the control group in efficacy of individual symptoms of Traditional Chinese Medicine, there was statistically significance between than two groups in dizziness, abdominal distension and anorexia symptoms, headache, heavy limbs numbness symptoms, palpitation, insomnia, chest pain symptoms, urine and stool abnormal symptoms (P<0.05). It was considered the treatment group of efficacy of individual symptoms of Traditional Chinese Medicine improved individual symptoms better than that of the control group.
3. Using chi square test to compare one group with the other group in the disappearance rate of efficacy of individual symptoms of Traditional Chinese Medicine after treatment, shows that in dizziness, headache, heavy limbs numbness, insomnia, chest pain, abnormal symptoms in the urine and stool, we compare the rate of%, the difference was statistically significance (P<0.05), can be considered individual symptoms in the treatment group rate was higher.
4. There was statistical significance compared before treatment with after treatment in tongue demonstration and pulse tracings,in which tongue pale, creamy fur, slippery pulse rate% loss of comparison by using chi square test to two group(P<0.05). It was considered the disappearance rate of the treatment group was higher.
5. There was statistical significance compared with the lipid parameters (TC, TG, HDL-C, LDL-C, Lp (a)) changes before and after treatment in both group by using paired t-test(P<0.05). It was showed that two cases of high blood lipid status had significantly improved. There was statistical significance between the two groups by t-test on the difference of TC> HDL-C. (P<0.05)
6. There was statistical significance between two groups using paired t test on the change of apolipoprotein (apoAI, apoB100) before and after treatment (P<0.05). It was showed that the two groups were remarkable improvements after treatment. The difference between groups had not statistical significance compared with two groups after treatment by using group t-test. (P>0.05).
7. There was significant difference between two groups of changes before and after treatment on the Hemorheological indexes (whole blood viscosity, high shear, low shear whole blood viscosity, plasma viscosity) by using paired t-test (P<0.05). It was showed that the two groups of such case indicators were improving significantly after treatment. The difference of plasma viscosity, erythrocyte sedimentation rate, hematocrit product, fibrinogen had statistical significance compared within groups after treatment by using paired t-test. (P<0.05)
Conclusion
The clinical study had shown that Jiang ZNP could effectively reduce the bulk lipid of the relevant laboratory index and could improve the syndrome symptoms and treatment of hyperlipidemia. In the process of taken medication, there was not significantly difference on the liver-kidney function, blood routine test, It was a safe and effective treatment medicine promoting the advantage of TCM and provided the theoretical basis for the further clinical application.
引文
[1]Pajak A, et al. Changer overtime in blood tipids and their correlates in polish rural and urban populations:the Poland-United States collaborative study in cardiopulmonary disease epidemiology. Ann Epidemiol,1997,7(2):115.
[2]吴兆苏.心血管系统疾病流行病学及防治[J].人民卫生出版社,2002：94.
[3]血脂治疗现状调查协作组.我国血脂异常治疗现状的调查[J].中华心血管病杂志,2001,29(1)：15.
[4]薛建欣.益气活血中药配伍对正常、血瘀大鼠血小板聚集及体外血栓形成的影响[J].中药药理与临床,1994：1-5.
[5]李甘地.病理学[M].北京：人民卫生出版社,2001：157.
[6]Turkoski BB. An otnce of prevent ion. Drugs used to treathyperlipidemia(Part 1) otthop Nurs,2004:23(1):58-61.
[7]马百坤,陈慧.载脂蛋白B-100基因突变与脂蛋白代谢及动脉粥样硬化[J].医学研究生学报,2005,7(7)：638-641.
[8]王振辉,董明纲.脂肪酸结合蛋白与高脂血症形成机制的研究进展[J].中国综合临床,2005,4(21)：375-376.
[9]The Expert Panel:Summary of the second report of the National Cholesterol Education Program(NCEP) Expert Panel on detection, evaluation and treatment of high cholesterol in adults(Adult Treatment PaneⅢ). JAMA,1993, 269:3015-3023.
[10]Sikand G, Kashyap ML, Wong ND, et al. Dietitian intervention improves lipid valties and saves medication costs in men with combined hyperlipidcmia and a history of niacin noncompllance. J Am Diet Assoc,2000,100:218-224.
[11]Nicklas BJ, Katzel LI, Busby-Whitehead J, et al. Increases in high-density lipoprotein cholesterol with endurance exercise training are blunted in obese compared With lcan men. Metabolism,1997,46:556-561.
[12]Despres JP, Pouliot MC, Moorjani S, et al.Loss of abdominal fat and metabolic response to exerci se training in obese women. Am J Physial,1991,26:159-167.
[13]Blumenthal JA, Matthews K, Fredrikson M, et al. Effects of exercise training on cardiovascular function and plasma lipid, lipoprotein and apo
"poprotein concentration in premenpausaI and postmenopausal women. Arterioscler Thromb,1991,11:912-917.
[14]Sopko G, Jacobs DR Jr, Jeffery R, et al. Effects on blood lipids and body weight in high risk men of a practical exercise program. AtherosclerosiS, 1983,49:219-229.
[15]杨燕,吴犬,何康.有氧运动及联用人参茎叶皂苷对脂质代谢的干预作用[J].中国药理学通报,1999,15：65-67.
[16]血脂异常防治对策专题组.血脂异常防治建议[J].中华心血管学杂志,1997,25：172.
[17]Blankenhorn DH, Azen SP, Kramseh DM, et al. MARS research group. Coronary angiographic changes with lovastatifl therapy:the monitored atherosclerosis regression study(MARS). Ann Intern Med,1993,119:969-976.
[18]Furberg CD, Adams HP Jr, Applegate WB, et al. For the asymptomatie carotid artery progression study(ACAPS)research group:effect of lovastatin on early carotid atheroscleroSiS and cardiovascular events. Cir,1994,90:1679-1687.
[19]Scandinavian Simvastatin Survival Study Group. Randomized trial of choleste rol l0wering in 4444 patients with coronary heart disease:the scandinavian sirevastatin Survival study(4S).Lancet,1994,344:1383-1389.
[20]ShePherd J. COhbe SM. Ford I, et al. Preventjon of coronary heart di Sease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study Group[J].N Engl J Med,1995,333:1301-1307.
[21]Allan Herd J, Ballantyne CM, Farmer JA, et al. For the LCAS investigators. Effect of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations(Lipoprotein and Coronary Atherosclerosis Study). Am J Cardiol,1997,80:278-286.
[22]Downs JR, Clearfield M, weis, et al. Primary prevention of acute coronary events with covastatin in men and women with average cholesterol levels. ResuIts of AFCAPS/TexCAPS[J]. JAMA.1998,279:1615-1622.
[23]Pitt B. waters D. Brown WV, et al. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease [J]. N Engl J Med.1999,341:70-76.
[24]徐成斌.冠心病防治在调脂领域的某些进展与动向[J].心血管病学进展,2002,23(1)：1-5.
[25]Frick MH, EloO, Haapa K, et al. Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med, 1987,317:1237-1245.
[26]Syvanna M, Nieminen MS, Frick MH, et al. A SSOCiations between lipoproteins and tlie progression of coronary and veingraft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation,1998,98:1993-1999.
[27]De Faire U, Ericsson CG, Grip L, et al. Secondary preventive potential of lipid-lowering drugs. The bezafibrate coronary atherosclerosis intervention trial(BECAIT). Eur Heart J 1996,7(Suppl):37-42.
[28]Gapinski JP, Vanruiswyk JV, Heudebert GR, et al. Prevent in grestenosis with fishoils following coronary angioplasty. Ameta-analysis. Arch Intern Med,1993,153:1595-1601.
[29]0'Brien JB, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after pereutaneous coronary interventions. JAM Coil Cardiol,1996,28:1111-1118.
[30]Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Cir,1995,92:2-4.
[31]Worz CR,Bottorff M. Treating dyslipidemic patients with lipid modifying and eombinatiOn therapies. Pharmacotherapy,2003,23(5):625-637.
[32]Chowdhury jR, Grossman M, Gupta S, et al. Long term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits[J]. Scjence,1991,254:1802-1805.
[33]Grossman M, Raper SE, Kozarshy K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia[J]. Nature Gene,1994,6:335-341.
[34]尹瑞立.家族性高胆固醇血症的基因诊断和基因治疗[J].心血管病学进展,1999,20(1)：9-13.
[35]Stein CS, Martins I, Davidson BL. Long-term reversal of hyperchol esterolemia in low density lipoprotein receptor(LDIR)-deficient mice by adenovi rUS · mediated LDLR gene transfer combined with CD154 blockade. J Gene Med,2000,2:41-45.
[36]Ashbouvne EKJ, LiuG, MiaoL, et al. Correction of hypertriglyce-ridemia and impai red fat tolerance in lipoprotein lipase-deficjent mice by adenovirus-mediated expression of human lipoprotein lipase[J]. A rteri-oscler Thromb Vase Biol,1997,17:532-539.
[37]Seguret-Mace S, Latta-Mahieu M, Castro G, et al. Potential gene therapy for lecithin-cholesterol acyltransferasd(LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene[J]. Circulation,1996,94(21):77-184.
[38]·Fan L, Owen JS, Diekson. Construction and characterization of polyci stronic retrovirus vectors for sustained and high-level coexpression of apolipoprotein A-I and lecithin-cholesterol acyltransferase[J] Atherosclerosis,1999,147(1):139-145.
[39]Hasty AH, Linton MRF, Brandt SJ, et al. Retroviral gene therapy in apoE-def iclent mice. ApoE experession jn the artery wall reduces early foam cell lesion formation[J]. Circulation,1999,99(2):571-576.
[40]Morishita R, Yamada S, Yamamoto K, et al. Novel therapeutic strategy for atherosclerosis:ribozyme oligonucleotides against apolipoprotein (a) selectively inhibit apolipoprotein(a)but not Plasminogen expression [J]. Circulation,1998,98:1898-904.
[41]Greeve J, Jona VK, Chowdhury NR, et al. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduction of Plasma LDL levels in normal and watanabe heritable hyperlipidemic rabbits[J].J Lipid Re.s,1996,37:2001-017.
[42]Laukkanen J, Lehtolainen P, Gough PJ, et al. Adenovirus-mediated gene transfer of a secreted form of human macrophage scavenger receptor inhibits modifled low-density lipoprotein degradation and foam-cell formation in macrophages[J]. Circulation,2000,101(19):1091-096.
[43]Koza rsky KF, Donahee MH, Glick JM, et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the choleslerol-fed LDL receptor-deficient mouse [J]. Arterioscler Thromb Vase Biol,2000,20(3):721-727.
[44]佟丽娟.高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2)：244.
[45]杨瑞合.“肾虚”与高脂血症发病关系的探讨[J].中西医结合杂志,1989,9(5)：313.
[46]龙庆余.从痰瘀辨治高脂血症60例[J].安徽中医临床杂志,1998,10(1)：20.
[47]罗列波.健脾消脂饮治疗高脂血症60例[J].河北中医,1999,2：92.
[48]桑海康.健脾益气、豁痰化疲法治疗高脂血症的疗效观察[J].辽宁中医杂志,2001,28(4)：208.
[49]熊文生,曾益宏.理脾化痰降脂片对高脂血症影响的临床研究[J].中国医药学报,2000,(2)：35.
[50]狄王文,亢秋云.降脂汤治疗高脂血症48例[J].陕西中医,1999,(8)：5.
[51]于世家.口服生大黄粉治疗高脂血症30例[J].中西医结合杂志,1986,6(8)：51.
[52]刘秀蓉.复方胡参合剂调血脂抗动脉硬化的临床研究[J].山东中医杂志,1996,15(7)：294.
[53]韦湘林,方显明.调脂口服液治疗高脂血症106例临床疗效观察[J].新中医,1999,(6)：12.
[54]卢亚娟.自拟平肝降脂丸治疗高血症45例[J].辽宁中医杂志,2000,27(4)：192.
[55]李绍鸿,宋崎云.降压散治疗原发性高血压并高脂血症的临床观察[J].云南中医学院学报,1999,22(1)：33.
[56]葛帮雨,王国斌.姜芩降脂片治疗高脂血症[J].中医研究,1998,11(4)：24.
[57]黄晓鸣.降脂清肝饮治疗高脂血症—脂肪肝临床研究[J].浙江中医学院学报,2000,4(2)：26.
[58]徐竺婷.自拟九味降脂汤治疗糖尿病伴高脂血症76例[J].上海中医杂志,1999,(12)30.
[59]朱秉匡.益寿调脂片调脂和抗自由基损伤的研究[J].广州中医药大学学报,1999,3(1)：13.
[60]胡正松.高脂血症从痰瘀论治五法[J].江苏中医,1995,16(12)：560.
[61]黄琦.轻身朵尔胶囊对肥胖女性患者体重及瘦素水平的影响[J].中国中西医结合杂志,2002,22(10)：780.
[62]刘仁人.固本降脂丸治疗中老年高脂蛋白血症临床观察[J].上海中医药杂志,1995,(10)：26.
[63]陈晓云.调脂散胶囊治疗老年原发性高脂血症的疗效观察[J].辽宁中医杂志,2001,28(6)：353.
[64]李振明.抵当丸治疗高脂血症69例[J].北京中医,1998,(4)：16.
[65]曾庆明.桃仁红花煎治疗无症状性高脂血症43例临床研究[J].新中医,2002,(4)6：20.
[66]张明华.降脂汤治疗高脂血症143例临床研究[J].江苏中医,1998,19(11)：13.
[67]杨雨鸣.消脂汤治疗高脂血症43例临床观察[J].江苏中医,1999,20(10)：31.
[68]浦斌红.浅析高脂血症的发病机理及中医药治疗[J].中医药研究,2000,16(3):29.
[69]曹枫.粘脂通冲剂治疗高脂、高粘血症的临床研究[J].河北中医, 1998,20(3)：134.
[70]王亚红,姜洪茹.降脂通脉方抗动脉粥样硬化后床研究[J].北京中医药大学学报,2000,5(3)：52.
[71]龙庆余.从痰瘀辨治高脂血症60例[J].安徽中医临床杂志,1998,10(1)：20.
[72]张柏丽.调肝导浊法中药抗高血脂及动脉硬化的研究[J].辽宁中医杂志,2002,29(8)：509.
[73]周仲瑛.从肝肾亏虚痰瘀痹阻辨治高脂血症的研究[J].南京中医药大学学报,1995,(2)：37.
[74]骆斌.抗粘降脂胶囊治疗高脂血症临床观察[J].北京中医药大学学报,1997,20(4)：56.
[75]李玉兰,贾长海.补肾通络方调整血脂50例临床观察[J].四川中医,2002,20(4)：30.
[76]翁维良.降脂药物研究[J].天津中医,1986,(1)：34.
[77]陈匡.降脂中药实验临床研究进展[J].医学综述,2002,8(6)：370.
[78]姜佳仓.中药丹参及大黄实验性高血脂症大鼠LDL受体基因表达的影响[J].中国病理生理杂志,1993,9(1)：108.
[79]闫道广.槲皮素、芦丁和BHT对低密度脂蛋白氧化修饰的抑制效应[J].第一军医大学学报,1995,1：24.
[80]薛彬,李可基.速溶山植饮料对高脂血症患者脂抗氧化酶和免疫功能的作用[J].中华预防医学杂志,2002,36(3)：172.
[81]牛满山.高脂血症临床治疗进展[J].中国中医药出版社,1991：81.
[82]孟振行.丹参对家兔实验性动脉粥样硬化预防作用的研究[J].心肺血管杂志,1995,2：101.
[83]黄维良.活血化痰瘀汤治疗高脂血症36例疗效观察[J].新中医,1998,30(9)：16.
[84]焦东海.大黄糖浆降脂作用的临床观察[J].中西医结合杂志,1989,9(8)：484.
[85]于晶,于占华.小承气汤加减治疗中风病高脂血症临床观察[J].长春中医学院学报,1999,15(4)：12.
[86]王利明.决明子药用研究[J].中医药学报,1993,8(3)：30.
[87]史培圣.首乌片治疗高脂血症疗效观察[J].中西医结合杂志,1989,9(8)：484.
[88]李宗其.柴胡降血脂疗效观察[J].中医杂志,1988,(2)：62.
[89]龙金江.八十年代以来柴胡及其方剂药理研究[J].甘肃中医学院学报,1992,(2)：50.
[90]于永红.赤芍、尼群地平对家兔实验性动脉粥样硬化病灶的消退作用[J].临床心血管病杂志,1996,3：164.
[91]邓柏颖.功能保健灸治疗高脂血症48例疗效观察[J].新中医,2002,4(9)：4.
[92]王华.丹参穴位注射治疗高脂血症40例临床分析[J].中国针灸,1997,17(8)：269.
[93]张丽.磁化针治疗高脂血症的疗效观察[J].中国针灸,2002,22(5)：33.
[94]卞震炯,徐铁锋.七味白术散合氟伐他汀片治疗脾虚痰浊型高脂血症[J].河南中医,2007,27(8)：60.
[95]杨坚毅.通脉降脂饮与辛伐他汀联合治疗高脂血症临床研究[J].四川中医,2003,21(11)：34-35.
[96]吴红铃,孙万峰.中药调脂汤配合西药治疗商脂血症60例[J].陕西中医,2005,26(7)：653-655.
[2]吴兆苏.心血管系统疾病流行病学及防治[J].人民卫生出版社,2002：94.
[3]血脂治疗现状调查协作组.我国血脂异常治疗现状的调查[J].中华心血管病杂志,2001,29(1)：15.
[4]薛建欣.益气活血中药配伍对正常、血瘀大鼠血小板聚集及体外血栓形成的影响[J].中药药理与临床,1994：1-5.
[5]李甘地.病理学[M].北京：人民卫生出版社,2001：157.
[6]Turkoski BB. An otnce of prevent ion. Drugs used to treathyperlipidemia(Part 1) otthop Nurs,2004:23(1):58-61.
[7]马百坤,陈慧.载脂蛋白B-100基因突变与脂蛋白代谢及动脉粥样硬化[J].医学研究生学报,2005,7(7)：638-641.
[8]王振辉,董明纲.脂肪酸结合蛋白与高脂血症形成机制的研究进展[J].中国综合临床,2005,4(21)：375-376.
[9]The Expert Panel:Summary of the second report of the National Cholesterol Education Program(NCEP) Expert Panel on detection, evaluation and treatment of high cholesterol in adults(Adult Treatment PaneⅢ). JAMA,1993, 269:3015-3023.
[10]Sikand G, Kashyap ML, Wong ND, et al. Dietitian intervention improves lipid valties and saves medication costs in men with combined hyperlipidcmia and a history of niacin noncompllance. J Am Diet Assoc,2000,100:218-224.
[11]Nicklas BJ, Katzel LI, Busby-Whitehead J, et al. Increases in high-density lipoprotein cholesterol with endurance exercise training are blunted in obese compared With lcan men. Metabolism,1997,46:556-561.
[12]Despres JP, Pouliot MC, Moorjani S, et al.Loss of abdominal fat and metabolic response to exerci se training in obese women. Am J Physial,1991,26:159-167.
[13]Blumenthal JA, Matthews K, Fredrikson M, et al. Effects of exercise training on cardiovascular function and plasma lipid, lipoprotein and apo
"poprotein concentration in premenpausaI and postmenopausal women. Arterioscler Thromb,1991,11:912-917.
[14]Sopko G, Jacobs DR Jr, Jeffery R, et al. Effects on blood lipids and body weight in high risk men of a practical exercise program. AtherosclerosiS, 1983,49:219-229.
[15]杨燕,吴犬,何康.有氧运动及联用人参茎叶皂苷对脂质代谢的干预作用[J].中国药理学通报,1999,15：65-67.
[16]血脂异常防治对策专题组.血脂异常防治建议[J].中华心血管学杂志,1997,25：172.
[17]Blankenhorn DH, Azen SP, Kramseh DM, et al. MARS research group. Coronary angiographic changes with lovastatifl therapy:the monitored atherosclerosis regression study(MARS). Ann Intern Med,1993,119:969-976.
[18]Furberg CD, Adams HP Jr, Applegate WB, et al. For the asymptomatie carotid artery progression study(ACAPS)research group:effect of lovastatin on early carotid atheroscleroSiS and cardiovascular events. Cir,1994,90:1679-1687.
[19]Scandinavian Simvastatin Survival Study Group. Randomized trial of choleste rol l0wering in 4444 patients with coronary heart disease:the scandinavian sirevastatin Survival study(4S).Lancet,1994,344:1383-1389.
[20]ShePherd J. COhbe SM. Ford I, et al. Preventjon of coronary heart di Sease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study Group[J].N Engl J Med,1995,333:1301-1307.
[21]Allan Herd J, Ballantyne CM, Farmer JA, et al. For the LCAS investigators. Effect of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations(Lipoprotein and Coronary Atherosclerosis Study). Am J Cardiol,1997,80:278-286.
[22]Downs JR, Clearfield M, weis, et al. Primary prevention of acute coronary events with covastatin in men and women with average cholesterol levels. ResuIts of AFCAPS/TexCAPS[J]. JAMA.1998,279:1615-1622.
[23]Pitt B. waters D. Brown WV, et al. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease [J]. N Engl J Med.1999,341:70-76.
[24]徐成斌.冠心病防治在调脂领域的某些进展与动向[J].心血管病学进展,2002,23(1)：1-5.
[25]Frick MH, EloO, Haapa K, et al. Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med, 1987,317:1237-1245.
[26]Syvanna M, Nieminen MS, Frick MH, et al. A SSOCiations between lipoproteins and tlie progression of coronary and veingraft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation,1998,98:1993-1999.
[27]De Faire U, Ericsson CG, Grip L, et al. Secondary preventive potential of lipid-lowering drugs. The bezafibrate coronary atherosclerosis intervention trial(BECAIT). Eur Heart J 1996,7(Suppl):37-42.
[28]Gapinski JP, Vanruiswyk JV, Heudebert GR, et al. Prevent in grestenosis with fishoils following coronary angioplasty. Ameta-analysis. Arch Intern Med,1993,153:1595-1601.
[29]0'Brien JB, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after pereutaneous coronary interventions. JAM Coil Cardiol,1996,28:1111-1118.
[30]Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Cir,1995,92:2-4.
[31]Worz CR,Bottorff M. Treating dyslipidemic patients with lipid modifying and eombinatiOn therapies. Pharmacotherapy,2003,23(5):625-637.
[32]Chowdhury jR, Grossman M, Gupta S, et al. Long term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits[J]. Scjence,1991,254:1802-1805.
[33]Grossman M, Raper SE, Kozarshy K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia[J]. Nature Gene,1994,6:335-341.
[34]尹瑞立.家族性高胆固醇血症的基因诊断和基因治疗[J].心血管病学进展,1999,20(1)：9-13.
[35]Stein CS, Martins I, Davidson BL. Long-term reversal of hyperchol esterolemia in low density lipoprotein receptor(LDIR)-deficient mice by adenovi rUS · mediated LDLR gene transfer combined with CD154 blockade. J Gene Med,2000,2:41-45.
[36]Ashbouvne EKJ, LiuG, MiaoL, et al. Correction of hypertriglyce-ridemia and impai red fat tolerance in lipoprotein lipase-deficjent mice by adenovirus-mediated expression of human lipoprotein lipase[J]. A rteri-oscler Thromb Vase Biol,1997,17:532-539.
[37]Seguret-Mace S, Latta-Mahieu M, Castro G, et al. Potential gene therapy for lecithin-cholesterol acyltransferasd(LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene[J]. Circulation,1996,94(21):77-184.
[38]·Fan L, Owen JS, Diekson. Construction and characterization of polyci stronic retrovirus vectors for sustained and high-level coexpression of apolipoprotein A-I and lecithin-cholesterol acyltransferase[J] Atherosclerosis,1999,147(1):139-145.
[39]Hasty AH, Linton MRF, Brandt SJ, et al. Retroviral gene therapy in apoE-def iclent mice. ApoE experession jn the artery wall reduces early foam cell lesion formation[J]. Circulation,1999,99(2):571-576.
[40]Morishita R, Yamada S, Yamamoto K, et al. Novel therapeutic strategy for atherosclerosis:ribozyme oligonucleotides against apolipoprotein (a) selectively inhibit apolipoprotein(a)but not Plasminogen expression [J]. Circulation,1998,98:1898-904.
[41]Greeve J, Jona VK, Chowdhury NR, et al. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduction of Plasma LDL levels in normal and watanabe heritable hyperlipidemic rabbits[J].J Lipid Re.s,1996,37:2001-017.
[42]Laukkanen J, Lehtolainen P, Gough PJ, et al. Adenovirus-mediated gene transfer of a secreted form of human macrophage scavenger receptor inhibits modifled low-density lipoprotein degradation and foam-cell formation in macrophages[J]. Circulation,2000,101(19):1091-096.
[43]Koza rsky KF, Donahee MH, Glick JM, et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the choleslerol-fed LDL receptor-deficient mouse [J]. Arterioscler Thromb Vase Biol,2000,20(3):721-727.
[44]佟丽娟.高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2)：244.
[45]杨瑞合.“肾虚”与高脂血症发病关系的探讨[J].中西医结合杂志,1989,9(5)：313.
[46]龙庆余.从痰瘀辨治高脂血症60例[J].安徽中医临床杂志,1998,10(1)：20.
[47]罗列波.健脾消脂饮治疗高脂血症60例[J].河北中医,1999,2：92.
[48]桑海康.健脾益气、豁痰化疲法治疗高脂血症的疗效观察[J].辽宁中医杂志,2001,28(4)：208.
[49]熊文生,曾益宏.理脾化痰降脂片对高脂血症影响的临床研究[J].中国医药学报,2000,(2)：35.
[50]狄王文,亢秋云.降脂汤治疗高脂血症48例[J].陕西中医,1999,(8)：5.
[51]于世家.口服生大黄粉治疗高脂血症30例[J].中西医结合杂志,1986,6(8)：51.
[52]刘秀蓉.复方胡参合剂调血脂抗动脉硬化的临床研究[J].山东中医杂志,1996,15(7)：294.
[53]韦湘林,方显明.调脂口服液治疗高脂血症106例临床疗效观察[J].新中医,1999,(6)：12.
[54]卢亚娟.自拟平肝降脂丸治疗高血症45例[J].辽宁中医杂志,2000,27(4)：192.
[55]李绍鸿,宋崎云.降压散治疗原发性高血压并高脂血症的临床观察[J].云南中医学院学报,1999,22(1)：33.
[56]葛帮雨,王国斌.姜芩降脂片治疗高脂血症[J].中医研究,1998,11(4)：24.
[57]黄晓鸣.降脂清肝饮治疗高脂血症—脂肪肝临床研究[J].浙江中医学院学报,2000,4(2)：26.
[58]徐竺婷.自拟九味降脂汤治疗糖尿病伴高脂血症76例[J].上海中医杂志,1999,(12)30.
[59]朱秉匡.益寿调脂片调脂和抗自由基损伤的研究[J].广州中医药大学学报,1999,3(1)：13.
[60]胡正松.高脂血症从痰瘀论治五法[J].江苏中医,1995,16(12)：560.
[61]黄琦.轻身朵尔胶囊对肥胖女性患者体重及瘦素水平的影响[J].中国中西医结合杂志,2002,22(10)：780.
[62]刘仁人.固本降脂丸治疗中老年高脂蛋白血症临床观察[J].上海中医药杂志,1995,(10)：26.
[63]陈晓云.调脂散胶囊治疗老年原发性高脂血症的疗效观察[J].辽宁中医杂志,2001,28(6)：353.
[64]李振明.抵当丸治疗高脂血症69例[J].北京中医,1998,(4)：16.
[65]曾庆明.桃仁红花煎治疗无症状性高脂血症43例临床研究[J].新中医,2002,(4)6：20.
[66]张明华.降脂汤治疗高脂血症143例临床研究[J].江苏中医,1998,19(11)：13.
[67]杨雨鸣.消脂汤治疗高脂血症43例临床观察[J].江苏中医,1999,20(10)：31.
[68]浦斌红.浅析高脂血症的发病机理及中医药治疗[J].中医药研究,2000,16(3):29.
[69]曹枫.粘脂通冲剂治疗高脂、高粘血症的临床研究[J].河北中医, 1998,20(3)：134.
[70]王亚红,姜洪茹.降脂通脉方抗动脉粥样硬化后床研究[J].北京中医药大学学报,2000,5(3)：52.
[71]龙庆余.从痰瘀辨治高脂血症60例[J].安徽中医临床杂志,1998,10(1)：20.
[72]张柏丽.调肝导浊法中药抗高血脂及动脉硬化的研究[J].辽宁中医杂志,2002,29(8)：509.
[73]周仲瑛.从肝肾亏虚痰瘀痹阻辨治高脂血症的研究[J].南京中医药大学学报,1995,(2)：37.
[74]骆斌.抗粘降脂胶囊治疗高脂血症临床观察[J].北京中医药大学学报,1997,20(4)：56.
[75]李玉兰,贾长海.补肾通络方调整血脂50例临床观察[J].四川中医,2002,20(4)：30.
[76]翁维良.降脂药物研究[J].天津中医,1986,(1)：34.
[77]陈匡.降脂中药实验临床研究进展[J].医学综述,2002,8(6)：370.
[78]姜佳仓.中药丹参及大黄实验性高血脂症大鼠LDL受体基因表达的影响[J].中国病理生理杂志,1993,9(1)：108.
[79]闫道广.槲皮素、芦丁和BHT对低密度脂蛋白氧化修饰的抑制效应[J].第一军医大学学报,1995,1：24.
[80]薛彬,李可基.速溶山植饮料对高脂血症患者脂抗氧化酶和免疫功能的作用[J].中华预防医学杂志,2002,36(3)：172.
[81]牛满山.高脂血症临床治疗进展[J].中国中医药出版社,1991：81.
[82]孟振行.丹参对家兔实验性动脉粥样硬化预防作用的研究[J].心肺血管杂志,1995,2：101.
[83]黄维良.活血化痰瘀汤治疗高脂血症36例疗效观察[J].新中医,1998,30(9)：16.
[84]焦东海.大黄糖浆降脂作用的临床观察[J].中西医结合杂志,1989,9(8)：484.
[85]于晶,于占华.小承气汤加减治疗中风病高脂血症临床观察[J].长春中医学院学报,1999,15(4)：12.
[86]王利明.决明子药用研究[J].中医药学报,1993,8(3)：30.
[87]史培圣.首乌片治疗高脂血症疗效观察[J].中西医结合杂志,1989,9(8)：484.
[88]李宗其.柴胡降血脂疗效观察[J].中医杂志,1988,(2)：62.
[89]龙金江.八十年代以来柴胡及其方剂药理研究[J].甘肃中医学院学报,1992,(2)：50.
[90]于永红.赤芍、尼群地平对家兔实验性动脉粥样硬化病灶的消退作用[J].临床心血管病杂志,1996,3：164.
[91]邓柏颖.功能保健灸治疗高脂血症48例疗效观察[J].新中医,2002,4(9)：4.
[92]王华.丹参穴位注射治疗高脂血症40例临床分析[J].中国针灸,1997,17(8)：269.
[93]张丽.磁化针治疗高脂血症的疗效观察[J].中国针灸,2002,22(5)：33.
[94]卞震炯,徐铁锋.七味白术散合氟伐他汀片治疗脾虚痰浊型高脂血症[J].河南中医,2007,27(8)：60.
[95]杨坚毅.通脉降脂饮与辛伐他汀联合治疗高脂血症临床研究[J].四川中医,2003,21(11)：34-35.
[96]吴红铃,孙万峰.中药调脂汤配合西药治疗商脂血症60例[J].陕西中医,2005,26(7)：653-655.